Brachytherapy · 2026
Long-term outcomes of real-time TRUS-guided HDR brachytherapy monotherapy for low and favorable intermediate-risk prostate cancer and predictive value of PSA nadir.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gaztañaga Miren, Escribano Carmen, Montero Beatriz, de Areba Javier, Martínez David Flavio, Galante Isabel, Serrano-Garcia Irene, Vázquez Manuel Gonzalo
Аннотация
PURPOSE: To report long-term oncologic outcomes and toxicity of real-time transrectal ultrasound (TRUS)-guided high-dose-rate (HDR) brachytherapy monotherapy for low-risk and favorable intermediate-risk prostate cancer treated with 13.5 Gy × 2 fractions.
METHODS AND MATERIALS: We performed a single-institution retrospective cohort study of consecutive patients treated with TRUS-guided, real-time planned HDR brachytherapy monotherapy (two fractions of 13.5 Gy separated by approximately two weeks). Biochemical failure was defined by the Phoenix definition. Kaplan-Meier methods estimated biochemical progression-free survival (bPFS) with 95% confidence intervals (CIs). Univariate Cox models explored associations between candidate predictors and bPFS. Toxicity was graded using CTCAE v4.
RESULTS: 300 patients were included with a median follow-up of 86.1 months [IQR 59.2 - 101.2]; the 5- and 10-year biochemical progression-free survival rates were 93.7% (95% CI: 91.0-96.6%) and 81.8% (95% CI: 76.0-87.9%), respectively. Late grade 2-3 genitourinary (GU) toxicity occurred in 20 patients (6.7%); no grade 4 events were observed. No grade ≥2 gastrointestinal (GI) toxicity was recorded.
CONCLUSIONS: Real-time TRUS-guided HDR brachytherapy monotherapy using 13.5 Gy × 2 provides durable long-term biochemical control with a favorable toxicity profile. Achieving a PSA nadir <0.2 ng/mL appears to be a strong predictor of biochemical control and merits incorporation into risk stratification and follow-up.
METHODS AND MATERIALS: We performed a single-institution retrospective cohort study of consecutive patients treated with TRUS-guided, real-time planned HDR brachytherapy monotherapy (two fractions of 13.5 Gy separated by approximately two weeks). Biochemical failure was defined by the Phoenix definition. Kaplan-Meier methods estimated biochemical progression-free survival (bPFS) with 95% confidence intervals (CIs). Univariate Cox models explored associations between candidate predictors and bPFS. Toxicity was graded using CTCAE v4.
RESULTS: 300 patients were included with a median follow-up of 86.1 months [IQR 59.2 - 101.2]; the 5- and 10-year biochemical progression-free survival rates were 93.7% (95% CI: 91.0-96.6%) and 81.8% (95% CI: 76.0-87.9%), respectively. Late grade 2-3 genitourinary (GU) toxicity occurred in 20 patients (6.7%); no grade 4 events were observed. No grade ≥2 gastrointestinal (GI) toxicity was recorded.
CONCLUSIONS: Real-time TRUS-guided HDR brachytherapy monotherapy using 13.5 Gy × 2 provides durable long-term biochemical control with a favorable toxicity profile. Achieving a PSA nadir <0.2 ng/mL appears to be a strong predictor of biochemical control and merits incorporation into risk stratification and follow-up.